A first New Zealand study looked at the role of lutetium-177-P SMA I &T in the progression of metastatic castrate-resistant prostate cancer
Loading...
Supplementary material
Other Title
Authors
Vyas, Madhusudan
Garett, N.
Lim, R.
Fagan, J.
Garett, N.
Lim, R.
Fagan, J.
Author ORCID Profiles (clickable)
Degree
Grantor
Date
2021-11
Supervisors
Type
Conference Contribution - Oral Presentation
Ngā Upoko Tukutuku (Māori subject headings)
Keyword
New Zealand
cancer patients
prostate cancer
theranostics
radionuclide therapy
Lu-177
Lutetium-177
neuroendocrine tumours (NETs)
metastatic castration-resistant prostate cancer (mCRPC)
mCRPC
cancer patients
prostate cancer
theranostics
radionuclide therapy
Lu-177
Lutetium-177
neuroendocrine tumours (NETs)
metastatic castration-resistant prostate cancer (mCRPC)
mCRPC
ANZSRC Field of Research Code (2020)
Citation
Vyas, M., Garett, N., Lim, R., & Fagan, J. (2021, November). A first New Zealand study looked at the role of lutetium-177-P SMA I &T in the progression of metastatic castrate-resistant prostate cancer. Paper presented at the National ITP Research Symposium 2021, Wellington, New Zealand.
Abstract
Prostate cancer that has spread beyond the prostate gland and is resistant to castration is a deadly disease that poses a threat to men's health. The current standard of care for metastatic prostate cancer is hormonal manipulation. However, metastatic castration-resistant prostate cancer (mCRPC) remains a significant treatment and management challenge. Recently, the use of lutetium-177 (Lu177) labelled ligands against PSMA was found to be compelling and resulted in an increase in overall patient survival.
Publisher
Permanent link
Link to ePress publication
DOI
Copyright holder
Authors
Copyright notice
All rights reserved